
## Lan Zhao

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7744545/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Histone Deacetylation Inhibition in Pulmonary Hypertension. Circulation, 2012, 126, 455-467.	1.6	222
2	Inhibition of pyruvate dehydrogenase kinase improves pulmonary arterial hypertension in genetically susceptible patients. Science Translational Medicine, 2017, 9, .	12.4	206
3	The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia. Nature, 2015, 524, 356-360.	27.8	113
4	Pathophysiology and Treatment of High-Altitude Pulmonary Vascular Disease. Circulation, 2015, 131, 582-590.	1.6	108
5	Heterogeneity in Lung <sup>18</sup> FDG Uptake in Pulmonary Arterial Hypertension. Circulation, 2013, 128, 1214-1224.	1.6	107
6	Beneficial Effects of Phosphodiesterase 5 Inhibition in Pulmonary Hypertension Are Influenced by Natriuretic Peptide Activity. Circulation, 2003, 107, 234-237.	1.6	102
7	Iron Homeostasis and Pulmonary Hypertension. Circulation Research, 2015, 116, 1680-1690.	4.5	97
8	Genetic Determination of Cardiac Mass in Normotensive Rats. Hypertension, 1999, 33, 949-953.	2.7	93
9	Dimethylarginine Dimethylaminohydrolase 2 Regulates Nitric Oxide Synthesis and Hemodynamics and Determines Outcome in Polymicrobial Sepsis. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, 1382-1392.	2.4	47
10	<i>miR-21</i> /DDAH1 pathway regulates pulmonary vascular responses to hypoxia. Biochemical Journal, 2014, 462, 103-112.	3.7	45
11	CLIC4/Arf6 Pathway. Circulation Research, 2019, 124, 52-65.	4.5	36
12	Supplementation with Iron in Pulmonary Arterial Hypertension. Two Randomized Crossover Trials. Annals of the American Thoracic Society, 2021, 18, 981-988.	3.2	28
13	Isoform-specific characterization of class I histone deacetylases and their therapeutic modulation in pulmonary hypertension. Scientific Reports, 2020, 10, 12864.	3.3	24
14	Hypoxiaâ€induced pulmonary hypertension—Utilizing experiments of nature. British Journal of Pharmacology, 2021, 178, 121-131.	5.4	20
15	Effects of Tetrahydrobiopterin Oral Treatment in Hypoxiaâ€Induced Pulmonary Hypertension in Rat. Pulmonary Circulation, 2014, 4, 462-470.	1.7	18
16	Tipifarnib prevents development of hypoxia-induced pulmonary hypertension. Cardiovascular Research, 2017, 113, 276-287.	3.8	16
17	The pathophysiological role of novel pulmonary arterial hypertension gene <i>SOX17</i> . European Respiratory Journal, 2021, 58, 2004172.	6.7	16
18	3′-Deoxy-3′-[18F]Fluorothymidine Positron Emission Tomography Depicts Heterogeneous Proliferation Pathology in Idiopathic Pulmonary Arterial Hypertension Patient Lung. Circulation: Cardiovascular Imaging, 2018, 11, e007402.	2.6	14

Lan Zhao

#	Article	IF	CITATIONS
19	Oxidation of PKGIα mediates an endogenous adaptation to pulmonary hypertension. Proceedings of the National Academy of Sciences of the United States of America, 2019, 116, 13016-13025.	7.1	12
20	Assessment of lung glucose uptake in patients with systemic lupus erythematosus pulmonary arterial hypertension: a quantitative FDG-PET imaging study. Annals of Nuclear Medicine, 2020, 34, 407-414.	2.2	11
21	Characterization of acute TLR-7 agonist-induced hemorrhagic myocarditis in mice by multi-parametric quantitative cardiac MRI. DMM Disease Models and Mechanisms, 2019, 12, .	2.4	5
22	Synthesis and <i>in vivo</i> behaviour of an exendin-4-based MRI probe capable of β-cell-dependent contrast enhancement in the pancreas. Dalton Transactions, 2020, 49, 4732-4740.	3.3	5
23	Clinical and genetic risk factors for venous thromboembolism in Chinese population. Frontiers of Medicine in China, 2010, 4, 29-35.	0.1	2
24	Sitafloxacin Expresses Potent Anti-Mycobacterium abscessus Activity. Frontiers in Microbiology, 2021, 12, 779531.	3.5	2
25	Application of [18F]FLTâ€PET in pulmonary arterial hypertension: a clinical study in pulmonary arterial hypertension patients and unaffected bone morphogenetic protein receptor type 2Åmutation carriers. Pulmonary Circulation, 2021, 11, 1-9.	1.7	1
26	Pathobiology of Pulmonary Hypertension. , 2022, , 530-541.		0
27	Abstract 230: Protein Farnesylation Inhibitor Tipifarnib Prevents Development of Chronic Hypoxia-induced Pulmonary Hypertension. Arteriosclerosis, Thrombosis, and Vascular Biology, 2015, 35, .	2.4	0